Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A140 (anti-EGFR chimeric mAb) plus mFOLFOX6 as first-line therapy in metastatic colorectal cancer
CTR20171667Phase 3Terminated
- Sponsor
- Kelun-Biotech
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in metastatic colon cancer (mCRC), Colon carcinoma (CC), rectal cancer, sponsored by Kelun-Biotech. Started Jan 2018; status: terminated.
02
Drugs
KL-140
03
Conditions
metastatic colon cancer (mCRC)Colon carcinoma (CC)rectal cancer
Beyond the preview
Go deeper on CTR20171667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171667.